Literature DB >> 14645563

Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Naoya Koizumi1, Hiroyuki Mizuguchi, Fuminori Sakurai, Teruhide Yamaguchi, Yoshiteru Watanabe, Takao Hayakawa.   

Abstract

The primary receptor, the coxsackievirus and adenovirus receptor (CAR), and the secondary receptor, alphav integrins, are the tropism determinants of adenovirus (Ad) type 5. Inhibition of the interaction of both the fiber with CAR and the penton base with the alphav integrin appears to be crucial to the development of targeted Ad vectors, which specifically transduce a given cell population. In this study, we developed Ad vectors with ablation of both CAR and alphav integrin binding by mutating the fiber knob and the RGD motif of the penton base. We also replaced the fiber shaft domain with that derived from Ad type 35. High transduction efficiency in the mouse liver was suppressed approximately 130- to 270-fold by intravenous administration of the double-mutant Ad vectors, which mutated two domains each of the fiber knob and shaft and the RGD motif of the penton base compared with those of conventional Ad vectors (type 5). Most significantly, the triple-mutant Ad vector containing the fiber knob with ablation of CAR binding ability, the fiber shaft of Ad type 35, and the penton base with a deletion of the RGD motif mediated a >30,000-fold lower level of mouse liver transduction than the conventional Ad vectors. This triple-mutant Ad vector also mediated reduced transduction in other organs (the spleen, kidney, heart, and lung). Viral DNA analysis showed that systemically delivered triple-mutant Ad vector was primarily taken up by liver nonparenchymal cells and that most viral DNAs were easily degraded, resulting in little gene expression in the liver. These results suggest that the fiber knob, fiber shaft, and RGD motif of the penton base each plays an important role in Ad vector-mediated transduction to the mouse liver and that the triple-mutant Ad vector exhibits little tropism to any organs and appears to be a fundamental vector for targeted Ad vectors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645563      PMCID: PMC296053          DOI: 10.1128/jvi.77.24.13062-13072.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR.

Authors:  M C Bewley; K Springer; Y B Zhang; P Freimuth; J M Flanagan
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

2.  An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.

Authors:  A I Kuzmin; O Galenko; R C Eisensmith
Journal:  Mol Ther       Date:  2001-03       Impact factor: 11.454

3.  Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Authors:  D A Einfeld; R Schroeder; P W Roelvink; A Lizonova; C R King; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Optimization of transcriptional regulatory elements for constructing plasmid vectors.

Authors:  Z L Xu; H Mizuguchi; A Ishii-Watabe; E Uchida; T Mayumi; T Hayakawa
Journal:  Gene       Date:  2001-07-11       Impact factor: 3.688

5.  Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors.

Authors:  K W Peng; L Pham; H Ye; R Zufferey; D Trono; F L Cosset; S J Russell
Journal:  Gene Ther       Date:  2001-10       Impact factor: 5.250

6.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.

Authors:  R Alemany; D T Curiel
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

7.  A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob.

Authors:  H Mizuguchi; N Koizumi; T Hosono; N Utoguchi; Y Watanabe; M A Kay; T Hayakawa
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

8.  Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism.

Authors:  P Leissner; V Legrand; Y Schlesinger; D A Hadji; M van Raaij; S Cusack; A Pavirani; M Mehtali
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

9.  Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity.

Authors:  K Aoki; S Furuhata; K Hatanaka; M Maeda; J S Remy; J P Behr; M Terada; T Yoshida
Journal:  Gene Ther       Date:  2001-04       Impact factor: 5.250

10.  Blood clearance rates of adenovirus type 5 in mice.

Authors:  Ramon Alemany; Kaori Suzuki; David T Curiel
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

View more
  22 in total

1.  Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

Review 4.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 5.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

6.  Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.

Authors:  Xinglei Yao; Yasuo Yoshioka; Tomohiro Morishige; Yusuke Eto; Shogo Narimatsu; Yasuaki Kawai; Hiroyuki Mizuguchi; Jian-Qing Gao; Yohei Mukai; Naoki Okada; Shinsaku Nakagawa
Journal:  Mol Ther       Date:  2011-06-14       Impact factor: 11.454

Review 7.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

8.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

9.  Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.

Authors:  Frederik H E Schagen; Harm C A Graat; Jan E Carette; Jort Vellinga; Michael A van Geer; Rob C Hoeben; Terence S Dermody; Victor W van Beusechem
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

10.  Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.

Authors:  Xiao Li; Yan Liu; Zhongmei Wen; Chang Li; Huijun Lu; Mingyao Tian; Kuoshi Jin; Lili Sun; Pegn Gao; Encheng Yang; Xiaohong Xu; Shifu Kan; Zhuoyue Wang; Yuhang Wang; Ningyi Jin
Journal:  Mol Cancer       Date:  2010-01-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.